Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants.

Published

Journal Article

OBJECTIVE: To report the incidence and management of elevated intraocular pressure (IOP) in patients with uveitis treated with the fluocinolone acetonide (FA) intravitreal implant. DESIGN: Pooled data from 3 multicenter, double-masked, randomized, controlled, phase 2b/3 clinical trials evaluating the safety and efficacy of the 0.59-mg or 2.1-mg FA intravitreal implant or standard therapy were analyzed. RESULTS: During the 3-year follow-up, 71.0% of implanted eyes had an IOP increase of 10 mm Hg or more than baseline and 55.1%, 24.7%, and 6.2% of eyes reached an IOP of 30 mm Hg or more, 40 mm Hg or more, and 50 mm Hg or more, respectively. Topical IOP-lowering medication was administered in 74.8% of implanted eyes, and IOP-lowering surgeries, most of which were trabeculectomies (76.2%), were performed on 36.6% of implanted eyes. Intraocular pressure-lowering surgeries were considered a success (postoperative IOP of 6-21 mm Hg with or without additional IOP-lowering medication) in 85.1% of eyes at 1 year. The rate of hypotony (IOP

Full Text

Duke Authors

Cited Authors

  • Goldstein, DA; Godfrey, DG; Hall, A; Callanan, DG; Jaffe, GJ; Pearson, PA; Usner, DW; Comstock, TL

Published Date

  • November 2007

Published In

Volume / Issue

  • 125 / 11

Start / End Page

  • 1478 - 1485

PubMed ID

  • 17923537

Pubmed Central ID

  • 17923537

International Standard Serial Number (ISSN)

  • 0003-9950

Digital Object Identifier (DOI)

  • 10.1001/archopht.125.11.ecs70063

Language

  • eng

Conference Location

  • United States